Patents Assigned to Elite Laboratories, Inc.
  • Patent number: 10213388
    Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: February 26, 2019
    Assignee: Elite Laboratories, Inc.
    Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
  • Patent number: 9056054
    Abstract: Aspects of the present invention are directed to abuse resistant oral dosage forms comprising a compressed microtablet that is coated with a water-retardant polymer. Additional aspects of the present invention are directed to an oral dosage form comprising an opioid agonist and at least one compressed microtablet coated with a water retardant polymer. The compressed microtablet may comprise an opioid antagonist.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: June 16, 2015
    Assignee: Elite Laboratories, Inc.
    Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
  • Patent number: 8703186
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: April 22, 2014
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Publication number: 20130230596
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Application
    Filed: April 16, 2013
    Publication date: September 5, 2013
    Applicant: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Patent number: 8425933
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: April 23, 2013
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Publication number: 20120189693
    Abstract: Aspects of the present invention are directed to oral dosage forms comprising a compressed microtablet, wherein said microtablet has a major dimension that is between about 0.25 mm and about 1.0 mm and comprises at least about 0.01 weight percent of at least one pharmaceutically active agent that is distributed substantially throughout said microtablet. Additional aspects of the present invention are directed to methods for producing compressed microtablets having a major dimension that is between about 0.25 mm and about 1.0 mm.
    Type: Application
    Filed: June 25, 2010
    Publication date: July 26, 2012
    Applicant: Elite Laboratories, Inc.
    Inventors: Christopher C. Dick, David F. Erkoboni, Charanjit R. Behl, Gary Bubb
  • Patent number: 8182836
    Abstract: An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release of the therapeutically effective amount of the opioid antagonist. An embodiment of the oral dosage form includes an opioid-antagonist layer coated onto a biologically inert pellet, and a non-releasing membrane coated onto the opioid-antagonist layer. Optionally, the oral dosage form can also include an opioid agonist, such that a method of preventing the abuse of an oral dosage form of an opioid agonist is provided by forming the oral dosage form including an opioid agonist and an opioid antagonist.
    Type: Grant
    Filed: June 5, 2009
    Date of Patent: May 22, 2012
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Patent number: 6984402
    Abstract: A dosage formulation for once daily administration prior to sleeping is described that provides an initial delay in pharmaceutical release followed by controlled release of the pharmaceutical. There is also provided a method for preparing a time specific delayed, controlled release formulation of dosage, which method includes coating a single pellet with at least one dosage layer, which is coated by at least one seal coat and at least one outer rate controlling layer of a water soluble polymer coat. The dosage formulation of this invention provides a substantially drug free interval of about 0 to 5 hours followed by a drug delivery interval at a rate permitting bioavailability thereof for up to about 24 hours following oral administration. A method of using the formulations of the present invention for the treatment of early morning pathologies, including atrial fibrillation, is also described.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: January 10, 2006
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta
  • Patent number: 6926909
    Abstract: A dosage formulation for once daily administration prior to sleeping is described that provides an initial delay in pharmaceutical release followed by controlled release of the pharmaceutical. There is also provided a method for preparing a time specific delayed, controlled release formulation of dosage, which method includes coating a single pellet with at least one dosage layer, which is coated by at least one seal coat and at least one outer rate controlling layer of a water soluble polymer coat. The dosage formulation of this invention provides substantially a drug free interval of about 0 to 5 hours followed by a drug delivery interval at a rate permitting bioavailability thereof for up to about 24 hours following oral administration. A method of using the formulations of the present invention for the treatment of early morning pathologies is also described.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: August 9, 2005
    Assignee: Elite Laboratories, Inc.
    Inventor: Atul M. Mehta